ClinicalTrials.gg
CompletedNCT00072865Updated Jan 26, 2007

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of Pemetrexed and Carboplatin in Breast Cancer and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 2 sites in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing pemetrexed in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Breast Neoplasms.

Enrollment
7th of 13
50 · median 50
Started
2003
with 2 others
Phase 2
10 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
10 of 14
Eli Lilly and Company

Among the 14 studies testing pemetrexed in Breast Neoplasms, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2003, is one of 10 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 14 studies testing pemetrexed in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing pemetrexed in Breast Neoplasms as a file.
02

Study summary

This is a nonrandomized study of pemetrexed plus carboplatin, with the primary objective of determining the efficacy of the combination in tumor reduction, in patients with locally advanced or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis of locally advanced or breast cancer
  • No prior chemotherapy for locally advanced or metastatic breast disease.
  • Patient may have received prior therapy finished greater than 1 year prior to enrollment.
  • Adequate bone marrow, liver and kidney function
  • criteria for disease status

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with pemetrexed
  • Pregnant or breast feeding
  • unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants

Interventions

06

What researchers measure

Primary outcomes

  1. antitumor activity

Secondary outcomes

  1. duration of response;time to progressive disease;time to treatment failure

07

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Moscow, Russia, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Saint Petersburg, Russia, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2003
First posted
Nov 13, 2003
Start
Jun 2003
Completion
Sep 2005
Last update
Jan 26, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 26, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00072865
First posted
Nov 13, 2003
Start date
Jun 2003
Completion
Sep 2005
Last update
Jan 26, 2007

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Carboplatin

Start the discussion